Introduction
Pulmonary congestion is a common finding in patients with heart failure (HF) and may itself contribute to worsening pulmonary vascular disease and biventricular HF.
1 Although the pathophysiologic mechanisms are incompletely understood, the presence of pulmonary congestion in patients with HF may identify those at higher risk for HF hospitalization and death, in both acute HF (AHF) and in HF. 3 -5 B-lines are hyperechoic artefacts on LUS which appear as vertical lines that arise from the pleural surface and can be quantified in several zones of the chest. 6 In the serial examination of patients with either chronic HF in the outpatient setting or with AHF requiring hospitalization, patient-reported symptom improvement and auscultation, in addition to other measures of treatment effect (e.g. urine output, weight loss), are currently used to guide therapy. In the absence of specific, quantitative measures, both over-and under-treatment may occur. Whereas over-treatment may result in orthostatic symptoms, including syncope or worsening renal function, under-treatment with associated residual congestion may lead to early readmission. 7, 8 In order to better delineate treatment targets for pulmonary congestion, the definition of both measurable treatment effects and prognostically relevant cut-off values is essential. 9 The goal of this systematic review was to describe the dynamic changes of LUS findings in patients with HF and to examine the prognostic utility of B-lines, as well as potential cut-off values, in patients with AHF or chronic HF. Our hypotheses were that the number of B-lines changes in response to therapy in patients with HF and that HF patients with a higher number of B-lines on LUS are at greater risk for adverse outcomes.
Methods
We collected data from clinical studies of adult patients with HF to examine the dynamic changes and prognostic utility of B-lines on LUS.
Literature search strategy
We searched the electronic databases PubMed, EMBASE and Web of Science using relevant terms detailed in the supplementary material online, Appendix S1.
Eligibility criteria for inclusion in this systematic review required that studies: were full-text articles written in English; studies in humans; conducted in adults; with a sample size of ≥25 patients; included patients with HF, and used LUS to assess dynamic changes and/or the prognostic value of pulmonary congestion. We excluded studies that were available in abstract form only, review articles, those focused on non-HF populations and those limited to the diagnosis of HF. We used the MOOSE (Meta-analysis Of Observational Studies in Epidemiology) checklist to describe the data collection process and to identify potential biases in included studies (supplementary material online, Table S1 ).
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Data synthesis and statistical analyses
We included all clinical studies regardless of setting, chronicity of HF and ejection fraction. Eligible studies were divided into four groups: (i) studies referring to dynamic changes in B-line number in response to HF therapy; (ii) studies referring to dynamic changes in B-line number in response to other interventions in patients with HF; (iii) studies referring to the prognostic value of B-lines in acute dyspnoea and AHF, and (iv) studies referring to the prognostic value of B-lines in chronic HF. Reported variables were selected based on their relevance to the study population, ultrasound methodology, intervention, study outcomes and potential confounders.
For the prognostic assessment at the time of discharge from hospitalization for AHF (Group 3), only those patients alive at the time of discharge and those with complete LUS data in Group 4 were included in the analyses. The HF hospitalization and all-cause mortality data for Groups 3 and 4 were reported as counts and percentages of the overall study cohort, and both unadjusted and adjusted hazard ratios (HRs) were reported, if available. In random-effect meta-analyses, we combined unadjusted HRs for B-lines as categorical and continuous variables in studies limited to patients with HF, stratified by pre-discharge LUS findings in patients with AHF vs. LUS findings in ambulatory patients with chronic HF. Heterogeneity was assessed and interpreted using the I 2 statistic and forest plots. A P-value of <0.05 was considered statistically significant. All analyses were performed using STATA Version 12.1 (Stata Corp. LLC, College Station, TX, USA).
Results
Monitoring of dynamic changes in B-lines Patients, settings and interventions
Results of the search and study selection are summarized in Figure 1 . We identified six studies in emergency department (ED) or hospitalized patients with dyspnoea or AHF (n = 25-152) ( Table 1) .
13,23 -27 One investigation assessed the impact of the change from a sitting to a supine position in ED patients with prior HF. 13 The remainder examined the impact of treatment during hospitalization for AHF; however, only two studies 26, 27 specified the type of HF treatment and none of them reported standardized HF treatment. Patients with known conditions that may contribute to B-line number independent of pulmonary oedema attributable to HF, such as pulmonary fibrosis or end-stage renal disease requiring dialysis, were excluded from some but not all publications (supplementary material online, Table S2 ).
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Ultrasound equipment, imaging protocols and analysis
Ultrasound equipment and imaging protocols are summarized in Table 1 . Investigators examined between four and 28 chest zones. Figure 2 illustrates two types of imaging protocols and LUS image examples with and without B-lines. 6, 11, 12 Several different quantification methods were employed. Broadly, these can be categorized in two groups, consisting of a count-based method in which B-lines across several prespecified chest zones are summed, and a score-based method, in which a chest zone is considered 'positive' if a certain number of B-lines are seen. Three studies 25, 26, 27 performed concomitant echocardiography at the time of LUS assessment and one also examined the presence of pleural effusions. 25 In four studies, 13, 23, 24, 27 B-lines were quantified by researchers who were blinded to some or all of the clinical findings; the remaining studies did not specify protocols for blinding (supplementary material online, Table S2 ).
Time interval and change in B-line number
Time intervals ranged from minutes to several days during the hospitalization and were not specified in one study. 25 All publications reported a change in B-line number or score following the intervention in question. Two AHF studies, which used the same 28-zone quantification method, reported mean changes of 22 B-lines [from a mean ± standard deviation (SD) of 53. to 31.7 ± 13.5; P < 0.01] after 24 h of treatment and 28 B-lines (from a mean ± SD of 48 ± 48 to 20 ± 23; P < 0.0001) between admission and discharge. 25, 26 Two other AHF studies examined B-lines in 11 zones and found a significant reduction in 'positive' LUS zones (based on a score) in 3 h of HF therapy, and between admission and discharge. 23, 27 Only one of the publications reviewed reported temporal blinding of the ultrasound readers 13 (supplementary material online, Table S2 ).
Prognostic value of lung ultrasound in heart failure
Patients and settings
We identified seven publications that reported on the prognostic utility of LUS.
14 -16,25,28-30 Two of these were conducted in hospitalized patients with acute dyspnoea (n = 66 and n = 290), 28, 29 three in patients hospitalized for AHF (n = 60 to n = 149) 15, 25, 30 and two in ambulatory chronic HF populations (n = 104 and n = 195) 14, 16 ( Table 2 ). The majority of studies included patients with HF with reduced ejection fraction (HFrEF) and patients with HF with preserved ejection fraction (HFpEF), but none presented results stratified by ejection fraction. Four studies excluded patients with conditions that may have contributed to an increased number of B-lines independently of pulmonary oedema due to HF 15, 16, 25, 30 (supplementary material online, Table S3 
Ultrasound equipment, imaging protocols and analysis
Ultrasound equipment and imaging protocols are summarized in Table 2 . In contrast to the acute dyspnoea and AHF studies, investigators used pocket ultrasound devices to acquire LUS images in two studies conducted in patients with chronic HF.
14,16
Imaging protocols were similar to those described for the assessment of dynamic changes in B-line number, used from five to 28 zones, and quantification methods included count and score measures. One study in chronic HF subjects also included the assessment of posterior lung zones.
14 In four investigations, B-line quantification was performed by researchers blinded to clinical findings, 15, 16, 28, 30 but only two of these specified whether the image analysis was performed in real time or offline 15, 16 (supplementary material online, Table S3 ). All acute dyspnoea and AHF studies reported the performance of concomitant echocardiography and two also reported assessment of pleural effusions. 25, 30 Neither of the studies in chronic HF reported concomitant assessment of echocardiography, but one included pleural effusions.
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Outcomes and meta-analysis
One publication that referred to a study performed in patients with acute dyspnoea reported intensive care unit mortality rates. 28 All other studies conducted in subjects with acute dyspnoea, AHF or chronic HF reported composite outcomes including HF AHF, acute heart failure; ED, emergency department; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; IQR, interquartile range; NR, not reported. Table S3 ). The mean or median age in the acute dyspnoea, AHF and chronic HF studies ranged from 50 years to 81 years. Median EF ranged from 37% to 48%. Rates of hospitalization for HF ranged between 6.9% and 25.0% and all-cause mortality ranged from 4.0% to 16.7% over the follow-up period. Unadjusted and adjusted HRs by B-line method and cut-off values are reported in Table 3 . Meta-analyses were performed for those AHF and chronic HF studies reporting composite outcomes of HF hospitalization (or worsening HF) and death. The pooled HR for readmission for HF at 3-5 months or death in 308 patients discharged from hospital after an AHF episode was 5.55 [95% confidence interval (CI) 2.24-13.80; P < 0.001], suggesting that a finding of ≥15 B-lines on 28-zone LUS identifies patients at risk for subsequent adverse events (Figure 3 ). This pooled HR should be interpreted in the context of the heterogeneity analysis comparing occurrence of these events across the three studies (I 2 = 40.3%, P = 0.187). 289 patients with chronic HF, the pooled HR for 6-month HF hospitalization or death was 3.41 (95% CI 2.02-5.75; P < 0.001), indicating that three or more B-lines in five to eight chest zones identifies patients at risk for these adverse events ( Figure 3) .
Incremental prognostic value of LUS findings
The incremental value of LUS beyond traditional risk markers was assessed in two studies. 15, 16 In one AHF study conducted in 60 patients, the addition of ≥30 B-lines (28 zones) at the time of discharge provided incremental prognostic information with respect to 3-month HF readmission or all-cause death beyond New York Heart Association (NYHA) class and baseline log BNP [integrated discrimination improvement (IDI) 15% (P = 0.02); continuous net reclassification improvement (NRI) 65% (P = 0.03)].
15 In a subset of 51 patients, the addition of log BNP did not provide incremental prognostic information beyond NYHA class, whereas ≥30 B-lines at the time of discharge may have [IDI 17%, (P = 0.09); continuous NRI 66%, (P = 0.07)]. Similarly, in one chronic HF study of 185 ambulatory patients (NYHA classes II-IV) with three or more B-lines (eight zones), the incremental prognostic value of LUS in AHF, acute heart failure; HF, heart failure; CV, cardiovascular; CXR, chest X-ray; ICU, intensive care unit; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; high-end, conventional ultrasound system; h/o, history of; NR, not reported; NYHA, New York Heart Association; PaO 2 , partial pressure of oxygen; Pocket, pocket ultrasound device. Figure 3 Unadjusted hazard ratios (HRs) for heart failure (HF) hospitalization or death with B-lines at hospital discharge in acute HF and chronic HF (n = 597). Cut-offs are >15 B-lines (28 zones) in acute HF pre-discharge from the hospital, and ≥3 B-lines (five to eight zones) in chronic HF (ambulatory) patients. The x-axis is on a logarithmic scale. CI, confidence interval.
comparison with auscultation as assessed by the IDI was 6.4% (95% CI 1.0-14.4) and 0.194 by the change in the area under the curve (ΔAUC) (95% CI 0.147-0.315; P = 0.001) for 6-month HF hospitalization or all-cause death. 16 The incremental prognostic value of LUS in comparison with a congestion score by the IDI was 6.6% (95% CI 1.9-15.1) and 0.136 by ΔAUC (95% CI 0.082-0.228; P = 0.002) for the primary outcome.
Discussion
This systematic review of clinical studies in adult patients with HF evaluated by LUS had two principal findings. Firstly, in patients hospitalized for AHF, the number of B-lines on LUS changes within as little as 3 h of HF treatment. The number of B-lines may also change within minutes following a change in position from sitting to supine. Secondly, among patients hospitalized for AHF, the finding of ≥15 B-lines on discharge in a 28-zone LUS identifies patients at a greater than five-fold risk for HF readmission or death. Similarly, in ambulatory patients with chronic HF, three or more B-lines on five-or eight-zone LUS marked those at a nearly four-fold risk for 6-month HF hospitalization or death. These data should be considered as hypothesis-generating given the heterogeneity of the AHF studies reviewed and overall small sample size.
Can lung ultrasound be used to monitor pulmonary congestion?
The quantitative assessment of adequate peripheral and pulmonary decongestion in HF continues to represent a challenge for both . are essential in order to evaluate the effects of current and new therapies, and to determine when therapy should be adjusted and when patients can be safely discharged from the hospital. Although based on a small number of studies, this systematic review suggests that LUS may enable tracking of changes in pulmonary congestion with treatment. The variations in imaging protocols and quantification methods, as well as a lack of standardized therapy, make the comparison of these trials difficult and hence our results must be interpreted with caution. Moreover, the lack of blinding of ultrasound readers (e.g. to clinical findings) may introduce bias. Based on the limited available data, scanning as few as 11 lung zones may provide sufficient information over the course of 3 h to a mean of 4.2 days to identify a change in the number of positive zones in patients hospitalized for AHF. These findings will need to be confirmed in larger, well-designed studies. At least based on the findings of one AHF study, patient positioning should be kept constant for serial assessments in order to avoid measurement of dynamic changes attributable to position change alone. This finding is in line with those from a study in which lung impedance appeared to be sensitive to changes in body position. 8 In a small trial of 25 AHF patients with HFrEF, the mean number of B-lines was slightly higher at baseline (mean ± SD: 53.4 ± 17.2) than that in a mixed HFrEF and HFpEF cohort of 100 AHF patients (mean ± SD: 48 ± 48) employing the same 28-zone scan protocol. Despite different time intervals, both studies reported significant changes in B-line number with HF therapy. Whether B-lines are similarly prevalent and change at similar rates in patients with HFrEF or HFpEF warrants further investigation.
Does lung ultrasound provide prognostic information in heart failure?
All-cause mortality rates in recent AHF trials including both patients with HFrEF and those with HFpEF range from 12% for 90 days to 11-21% for 180 days of follow-up. 11 All-cause mortality rates were lower (4.0% and 7.4%) in two of the AHF trials 25, 30 we reviewed despite follow-up periods and age ranges similar to those in recent AHF trials. However, these AHF trials enrolled patients with lower mean ejection fraction than the trials included in our review, which may explain the associated higher mortality rates in these trials. Reported rates for HF readmissions varied substantially among the studies reviewed, and, with the exception of one, 15 were lower than those in recent AHF trials (6% for 30 days), AHF registries or national databases (24-31% for 30-90 days).
19 -21 The lower event rates, especially for HF readmissions, in the publication by Gargani et al. 25 may explain the heterogeneous results of the meta-analysis for the AHF trials reviewed. The 6-month event rates in the two LUS studies in patients with chronic HF 14, 16 were relatively high compared with those in recent trials conducted in patients with chronic HF and HFrEF or HFpEF. 22 Nevertheless, our data suggest that a high number of B-lines identifies patients at greater risk for subsequent HF hospitalization and mortality in studies of both AHF and chronic HF. Findings of studies reporting the evaluation of fewer chest zones (five to eight) seem to provide prognostic information similar to that of studies in which a higher number of zones were evaluated (e.g. 28 zones). The potential utility of protocols evaluating fewer chest zones is an important area of research and requires further investigation. By reducing the number of zones scanned, and thereby reducing examination time, the test will potentially become more widely used. Standardized image acquisition and analysis by investigators blinded to clinical findings will be important to allow the comparison of study results across trials and the development of meaningful cut-off values.
Current gaps in knowledge
Based on this systematic review, there are a number of gaps in the current literature. It is unclear what an important or sufficient change in B-line number in response to standardized treatment for AHF is and whether adequately treated AHF patients at the time of discharge should achieve a similarly low B-line number as ambulatory patients with chronic HF. Standardized reporting of LUS measures (e.g. number of zones), both continuous and categorical, will be an important feature of future HF trials reporting LUS findings in order to facilitate the comparison of findings across trials. There is also a lack of data describing the prevalence of LUS findings in different HF phenotypes such as HFrEF and HFpEF, in both AHF and chronic HF, as well as the response to therapy by HF group and prognostically important cut-off values. In addition, the incremental value of LUS in the monitoring and prognosis of patients with HF beyond other markers of congestion and risk in this population warrants further investigation. . 
Limitations
Our systematic review is limited by the small number of studies and small sample sizes in which dynamic changes and the prognostic value of LUS findings in HF are reported. Further, the small sample size allowed for only limited assessment of the incremental value of LUS beyond traditional clinical and biochemical risk markers such as congestion score, NYHA class and natriuretic peptides. In addition, the lack of standardization of the number of chest zones evaluated and method of B-line quantification makes it difficult to compare findings across studies and to perform meta-analyses. Nevertheless, we believe that this systematic review provides hypothesis-generating data that can inform future HF trials.
Conclusions
Among patients hospitalized for AHF, the number of B-lines on LUS decreases with HF treatment. A large number of B-lines in patients with either AHF or chronic HF identifies those at high risk for HF hospitalization or death. These data suggest that LUS may represent a useful, non-invasive method of tracking dynamic changes in pulmonary congestion in response to treatment and that residual congestion at the time of discharge or in ambulatory patients with chronic HF may identify those at high risk for decompensation.
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